공시 • Mar 19
SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026 SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israel 공시 • Mar 10
SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026 SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026 공시 • Jan 07
SofWave Medical Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025 SofWave Medical Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. for the quarter, the company expects total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year.
for the year, revenue is expected to total between $87.3 million and $87.6 million, as compared to approximately $59.7 million in the same period last year, reflecting an increase of approximately 46% compared to the same period last year. 공시 • Oct 20
SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025 SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025 공시 • Sep 04
Sofwave Medical Ltd. Receives FDA, Pre-market Clearance for Pure Impact VIP Standalone EMS Device for Comprehensive Multi-Body Area Muscle Strengthening and Firming Sofwave Medical Ltd. announced that the Company has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA). This clearance expands the Pure Impact™? product line further via the launch of a standalone EMS Device branded Pure Impact VIP™?. The Pure Impact VIP™? is designed as a standalone system that can be delegated and administered by staff using a simple and intuitive procedure. 공시 • Aug 12
Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million. Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million on August 7, 2025. A cash consideration valued at ILS 27.12 per share will be paid by Migdal Insurance.
Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) completed the acquisition of 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) on August 7, 2025. 공시 • Jul 16
SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025 SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025 공시 • Apr 25
Sofwave’S Lifthd Body Contouring Applicator to Debut At the 44Th Annual Meeting of the American Society for Laser Medicine and Surgery (Aslms) 2025 SofWave Medical Ltd. announced activities around the official launch of the liftHD high density body contouring handpiece at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 on energy-based medicine and science being held at the Orange County convention Center in Orlando, Florida, from April 24- 26, 2025. Sofwave’s onsite exhibition booth will be active throughout the event, showcasing the liftHD non-invasive aesthetic body contouring applicator as well as the Sofwave family of SUPERB™ and Pure Impact™ product lines. The new body contouring applicator benefits patients by utilizing the same precise SUPERB™ pulse technology as with the SUPERB™ line of treatments but with broader, higher density controlled thermal zones resulting in less pulses per treatment, thereby reducing treatment time by ~40%. The liftHD applicator by Sofwave is the Company’s newest applicator and provides the opportunity to deliver next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance to achieve SUPERB results beyond the face. This body applicator’s user-friendly, ergonomic design was specifically made to deliver fast, efficient, comfortable treatments. SUPERB™ Treatment Technology is Not Only Different But Better than the Competition.Precise depth control – The thermal treatment zone is precisely placed between 0.5mm and 1.8 mm to stimulate natural healing and collagen, elastin, and hyaluronic acid production. Optimized Energy Delivery - Optimal dermal timulation is achieved by parallel heating the dermis to a temperature of 149-158°F for a controlled, predictable, and dermally selective treatment outcome.Unique Broad Tissue Coverage - Seven parallel beam transducers simultaneously create large, controlled 3D cylindrical thermal zones with each pulse, resulting in optimal treatment coverage in just one 30–45-minute treatment. In addition, clinicians continue to expand the body of clinical evidence and case studies which strongly supporting the benefits of the Sofwave™ family of products and treatments. 공시 • Apr 21
Sofwave Medical Ltd.'s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region Sofwave Medical Ltd. announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave's SUPERB™? Technology. Market approval in Japan further extends Sofwave's sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea. 공시 • Mar 10
SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025 SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israel 공시 • Jan 14
Sofwave Medical Provides Earnings Guidance for Fourth Quarter and Full Year 2024 Sofwave Medical Provided Earnings Guidance for fourth quarter and full year 2024. For the quarter, the company expects revenue to total between $18.2 million and $18.4 million, as compared to approximately $15.3 million in the same period last year, reflecting an increase of approximately 20% compared to the same period last year.
For the full year 2024, the company expects revenue to total between $59.5 million and $59.7 million, as compared to approximately $50.3 million in the same period last year, reflecting an increase of approximately 19% compared to the same period last year. 
